Pomerantz Law Firm Launches Investigation into Valneva SE Following Troubling Safety Concerns

Pomerantz Law Firm Investigates Valneva SE Claims

The Pomerantz Law Firm has initiated an investigation regarding potential securities fraud affecting investors of Valneva SE, a biotech company listed on NASDAQ under the ticker VALN. This inquiry arises after alarming reports related to the safety of Valneva's chikungunya virus vaccine (IXCHIQ), which has reportedly impacted the stock price significantly.

On February 25, 2025, the U.S. Centers for Disease Control and Prevention (CDC) posted a critical notice stating that they were looking into five cases of cardiac or neurologic issues that occurred in individuals aged 65 and older after vaccination with IXCHIQ. The announcement triggered a considerable market reaction, resulting in Valneva’s American Depositary Receipt (ADR) plummeting by $1.06, a decline of 13.57%. By the close of trading on February 28, 2025, the ADR was valued at only $6.75.

The situation deteriorated further on August 22, 2025, when the U.S. Food and Drug Administration (FDA) suspended the marketing application for IXCHIQ due to ongoing safety concerns. This news led to Valneva’s ADR suffering a steep decline of $2.21, equating to a drop of 18.99%, by the end of August 25, 2025, lowering the ADR price to $9.43.

Given these severe developments, the Pomerantz Law Firm urges those investors who have experienced financial losses linked to these events to step forward. The firm’s founding principles are rooted in protecting the rights of shareholders, and this investigation is a part of their longstanding tradition of holding corporations accountable for any misconduct.

Pomerantz LLP has been a leader in corporate and securities class action litigation for over 85 years, recovering millions for shareholders affected by fraud and corporate malfeasance. The firm’s legal experts are highly regarded, operating from various major cities including New York, Chicago, Los Angeles, London, Paris, and Tel Aviv. They are recognized for their deep commitment to fighting injustice in the realm of securities fraud and have built a reputation as one of the premier firms in this field.

Investors impacted by these recent events or who wish to join the class-action suit can contact Pomerantz for assistance. Attorney Danielle Peyton can be reached via email at [email protected] or by phone at 646-581-9980, ext. 7980.

As this situation continues to evolve, stakeholders will be keeping a close eye on Valneva and the ongoing developments related to IXCHIQ. The ramifications of these issues could be significant, not only for Valneva’s financial standing but also for the public's health concerns regarding the vaccine. Updates from both the CDC and FDA will play a critical role in shaping the company’s future and should inform investor decisions in the coming weeks.